Dr. Reddy’s Laboratories (RDY) Earns Daily News Sentiment Rating of 0.14
Headlines about Dr. Reddy’s Laboratories (NYSE:RDY) have trended somewhat positive on Wednesday, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dr. Reddy’s Laboratories earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.3485646294889 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern’s analysis:
- The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Dr. Reddy’s Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (finance.yahoo.com)
- Comparing Dr. Reddy’s Laboratories (RDY) and Its Peers (americanbankingnews.com)
- RDY EQUITY ALERT: The Law Offices of Vincent Wong Reminds … – Business Wire (press release) (businesswire.com)
- EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm (finance.yahoo.com)
- Mid-Afternoon Market Update: Dow Rises Over 50 Points; T2 Biosystems Shares Plummet – Benzinga (benzinga.com)
RDY has been the topic of several analyst reports. Zacks Investment Research raised Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, July 14th. CLSA raised Dr. Reddy’s Laboratories from an “underperform” rating to an “outperform” rating in a research report on Thursday, August 31st. Jefferies Group LLC reiterated a “sell” rating and set a $31.62 price target on shares of Dr. Reddy’s Laboratories in a report on Sunday, September 3rd. Finally, BidaskClub lowered Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $31.62.
Shares of Dr. Reddy’s Laboratories (NYSE RDY) opened at 34.56 on Wednesday. The company’s 50-day moving average price is $32.97 and its 200-day moving average price is $38.79. The company has a market capitalization of $5.73 billion, a price-to-earnings ratio of 32.21 and a beta of 0.34. Dr. Reddy’s Laboratories has a one year low of $29.83 and a one year high of $50.10.
TRADEMARK VIOLATION WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/dr-reddys-laboratories-rdy-earns-daily-news-sentiment-rating-of-0-14/1574465.html.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.